Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing new product candidates for rare diseases and other serious conditions. Its product candidates include Dyscorban (ifetroban), Vasculan (ifetroban) and Fibroban. Dyscorban (ifetroban) oral capsule is being developed for the treatment of the cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Vasculan (ifetroban) oral capsule has been developed for the treatment of systemic sclerosis (SSc), also known as scleroderma. It is a rare autoimmune disorder that results in a thickening of the skin and internal organs. Fibroban oral capsule is developed for the treatment of idiopathic pulmonary fibrosis (IPF). Its commercial products include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Acetadote (acetylcysteine) injection has been developed for the treatment of acetaminophen poisoning. Caldolor (ibuprofen) injection is developed for the treatment of pain and fever.
Back to dashboard
Company Information
About this company
Key people
A. J. Kazimi
Chairman of the Board, Chief Executive Officer
John M. Hamm
Chief Financial Officer, Vice President
Todd M. Anthony
Vice President - Organizational Development
Martin S. Brown
Director
Gordon R. Bernard
Independent Director
Joseph C. Galante
Independent Director
James R. Jones
Independent Director
Kenneth J. Krogulski
Independent Director
Click to see more
Key facts
- Shares in issue14.98m
- EPICCPIX
- ISINUS2307701092
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$97.69m
- Employees93
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.